Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - daniel+powell

3 Results Sort By:

CAR T cell therapy for the treatment of ovarian cancer and other gynecologic malignancies

Anti-Mullerian inhibiting substance type II receptor (MISRII) specific CAR T cell therapy for the targeted, safe treatment of ovarian cancer. Technology Overview: Ovarian cancer is the 5th leading cause of cancer-related deaths in women and is the most lethal of all gynecologic malignancies with an overall 5-year survival rate of 46%. The Müllerian...

Published: 3/11/2020

Inventor(s):

Keywords(s):

 

Category(s):

Fully human anti-mesothelin CAR with low immunogenicity for in vivo persistence of anti-tumor engineered T cells

The fully human CAR targets mesothelin, a surface protein overexpressed in several cancer types. P4, a human antibody fragment that binds human mesothelin with high specificity, is fused to T cell signaling domains such as 28z. The T cells engineered to express this CAR are shown to shrink tumors in a mouse model bearing human ovarian tumors overexpressing...

Published: 1/29/2020

Inventor(s):

Keywords(s):

Category(s):

Single viral vector for expression of both CAR/TCR and immune modulators for cancer immunotherapy

A single lentiviral vector system as an expression platform for constitutive immune receptor expression and inducible antigen-dependent immunomodulatory molecule expression in primary immune cells for enhanced immunotherapy efficacy Problem: Adoptive cancer immunotherapy, like chimeric antigen receptor T cell (CAR T) therapy, has had extraordinary...

Published: 1/23/2019

Inventor(s):

Keywords(s):

 

Category(s):